✦ LIBER ✦

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

✍ Scribed by Olson, E. M.; Abdel-Rasoul, M.; Maly, J.; Wu, C. S.; Lin, N. U.; Shapiro, C. L.

Book ID: 121390227
Publisher: Oxford University Press
Year: 2013
Tongue: English
Weight: 243 KB
Volume: 24
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdt036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence of central nervous system meta

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

✍ Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.- H.; Quah, C.; Lee, L. F.; Cortes, 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 145 KB

Central nervous system metastases in a c

Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab

✍ E. Montagna; G. Cancello; D. D’Agostino; R. Lauria; V. Forestieri; A. Esposito; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 234 KB

High recurrence risk and use of adjuvant

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

✍ Akiyo Horio; Takashi Fujita; Hironori Hayashi; Masaya Hattori; Naoto Kondou; Mai 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 505 KB

744: Clinical and histopathological char

744: Clinical and histopathological characteristics of HER2-positive breast cancer in patients treated with adjuvant trastuzumab

✍ Jurcic, P. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 63 KB

The risk of central nervous system metas

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

✍ Filippo Montemurro; Massimo Aglietta 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 2 views

The risk of central nervous system metas

The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

✍ Rose Lai; Chau T. Dang; Mark G. Malkin; Lauren E. Abrey 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

## Abstract ## BACKGROUND Trastuzumab, which is a large monoclonal antibody that is efficacious in the treatment of patients with HER‐2/__neu__‐overexpressing, metastatic breast carcinoma, does not penetrate the blood‐brain barrier and, thus, may allow the brain to become a sanctuary site for micr